GNH USA

Europe — EMA

Naos (Salbutamol Sulfate, Ipratropium Bromide)

GNH USA supplies Naos (Salbutamol/Ipratropium), a bronchodilator for asthma and chronic obstructive pulmonary disease. Request a quote for global supply.

Salbutamol Sulfate, Ipratropium Bromide

Request sourcing

1
Pack/s

What is Salbutamol Sulfate, Ipratropium Bromide?

Salbutamol Sulfate and Ipratropium Bromide, the active ingredients in Naos, are bronchodilators presented as an inhalation product for respiratory use. They treat obstructive airway diseases such as asthma and chronic obstructive pulmonary disease in adults and children when prescribed by a healthcare professional.

GNH USA supplies Naos as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand. Logistics are coordinated to ensure timely delivery across continents.

What is Salbutamol Sulfate, Ipratropium Bromide used for?

Naos, a combination bronchodilator, is used to manage obstructive airway diseases by relaxing airway smooth muscle.

- Asthma: provides rapid bronchodilation to relieve acute symptoms. - Chronic obstructive pulmonary disease (COPD): improves airflow and reduces frequency of exacerbations. - Exercise‑induced bronchoconstriction: prevents bronchospasm during physical activity. - Bronchospasm associated with allergic reactions: mitigates airway narrowing during allergen exposure. - Reversible airway obstruction: restores ventilation in patients with reversible airway limitation.

What are the side effects of Salbutamol Sulfate, Ipratropium Bromide?

Adverse reactions to Naos may vary in frequency and severity.

Common Side Effects: - Tremor - Dry mouth - Cough

Serious or Rare Side Effects: - Paradoxical bronchospasm - Angioedema - Tachycardia

What precautions apply to Salbutamol Sulfate, Ipratropium Bromide?

Before prescribing Naos, clinicians should consider several safety aspects.

- Cardiac assessment: monitor for tachycardia or arrhythmias. - Glaucoma caution: anticholinergic component may increase intra‑ocular pressure. - Severe COPD exacerbation: use with close medical supervision. - Concomitant MAO inhibitors: may potentiate sympathomimetic effects. - Store at room temperature: keep in original container, protect from moisture and heat.

What does Salbutamol Sulfate, Ipratropium Bromide interact with?

Naos can interact with other medicines; awareness of the interaction level is important.

Major Interactions (Avoid): - Beta‑blockers: may diminish bronchodilator efficacy. - MAO inhibitors: can increase sympathomimetic activity. - Tricyclic antidepressants: may enhance cardiovascular effects.

Moderate Interactions (Monitor Closely): - Diuretics: risk of hypokalemia may be heightened. - Theophylline: additive bronchodilation may provoke tachyarrhythmia. - Other anticholinergics: may increase anticholinergic burden such as dry mouth.

Frequently asked questions

What is Naos used for?+
Naos is a prescription inhalation product that combines salbutamol sulfate and ipratropium bromide to treat obstructive airway diseases. It is indicated for relief of bronchospasm in asthma, management of chronic obstructive pulmonary disease (COPD), and prevention of exercise‑induced bronchoconstriction when used as directed by a healthcare professional.
How does salbutamol and ipratropium work together in Naos?+
Salbutamol activates β2‑adrenergic receptors on airway smooth muscle, triggering a cascade that raises cyclic AMP and causes muscle relaxation. Ipratropium blocks muscarinic M3 receptors, preventing acetylcholine‑mediated contraction. By simultaneously stimulating bronchodilation and inhibiting bronchoconstriction, the two agents produce a synergistic widening of the airways.
What is the usual dose of Naos?+
The dose of Naos is individualized by the prescribing clinician based on the patient’s age, disease severity, and response to therapy. Typical regimens involve a specific number of inhalations per dose and a defined frequency, but exact dosing instructions must be obtained from the prescriber’s order.
Is Naos safe to use during pregnancy or breastfeeding?+
Safety data for Naos in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers should evaluate each case and discuss potential risks and alternatives with the patient.
How do I order Naos from GNH USA?+
To request Naos, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.
How does Naos compare with using a single‑component inhaler?+
A single‑component inhaler contains either a β2‑agonist or an anticholinergic agent, providing bronchodilation through one pathway. Naos combines both mechanisms in one device, offering broader airway relaxation, potentially faster symptom control, and the convenience of a single inhaler, which can improve adherence compared with using two separate products.
What are the storage and handling requirements for Naos?+
Naos should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and direct sunlight. Keep the inhaler cap closed when not in use and avoid exposing the device to extreme temperatures or humidity, which could affect aerosol performance.
How is Naos administered to patients?+
Naos is delivered via inhalation using a metered‑dose inhaler. The patient should shake the device, exhale fully, place the mouthpiece in the mouth, and inhale slowly and deeply while actuating the inhaler. After each puff, hold the breath for several seconds before exhaling. Proper technique should be demonstrated by a healthcare professional.
What are the most serious risks associated with Naos?+
Serious adverse events, although rare, include paradoxical bronchospasm, angioedema, and significant tachycardia or other cardiac arrhythmias. If any of these occur, the patient should seek immediate medical attention, discontinue the inhaler, and inform their healthcare provider promptly.
Who should not use Naos?+
Naos is contraindicated in patients with a known hypersensitivity to salbutamol, ipratropium, or any excipients in the formulation. Caution is also advised for individuals with severe cardiovascular disease, uncontrolled narrow‑angle glaucoma, or those taking non‑selective β‑blockers, as these conditions may increase the risk of adverse reactions.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Salbutamol Sulfate, Ipratropium Bromide
Route
Inhalation Use
Manufacturer
Neopharmed Gentili Spa
Origin
EU

Related products

Almeida

Almeida

Salbutamol Sulfate, Ipratropium Bromide

I.B.N. Savio S.R.L.
EU
Berovent

Berovent

Salbutamol Sulfate, Ipratropium Bromide

Boehringer Ingelheim Hellas Single Member S.A.
EU
Biwind

Biwind

Salbutamol Sulfate, Ipratropium Bromide

Neopharmed Gentili Spa
EU
Butapral

Butapral

Salbutamol Sulfate, Ipratropium Bromide

Genetic Spa
EU